Janssen pulls plug on Alzheimer’s candidate
Safety concerns have prompted Janssen to pull the plug on a development programme testing the BACE inhibitor atabecestat for Alzheimer’s disease.
Read More
Tag: atabecestat
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
